Board-certified anesthesiologist brings nearly two decades of clinical experience in intravenous therapy, advanced patient monitoring, and scientific research to Alpha Vital Elite Precision Medical IV’s personalized approach to wellness, healthy aging, and support for chronic disease managemen

New York, USA

As intravenous wellness therapies become increasingly common in spas, wellness centers, mobile services, and at-home settings, one question is becoming increasingly important: Who is making the medical decisions, and who is prepared to respond if something goes wrong?

That question lies at the heart of Alpha Vital Elite Precision Medical IV, a physician-directed medical wellness practice founded on individualized patient evaluation, continuous medical monitoring, evidence-informed decision-making, and the direct on-site presence of a physician.

Dr. Violeta Aronov, a board-certified anesthesiologist with nearly two decades of experience administering intravenous medications and monitoring patients, founded Alpha Vital Elite Precision Medical IV to clearly distinguish physician-led medical wellness from the increasingly common IV bar and medspa model.

“The moment a substance enters a patient’s vein, it becomes a medical intervention—not a spa service,” Dr. Aronov said. “Starting an IV is a technical skill that trained nurses perform every day. But determining whether an infusion is medically appropriate, understanding how it may affect the body, and recognizing and managing complications require a physician’s training, clinical judgment, and oversight.”

Bringing Medical Standards Into the Wellness Environment

IV therapy has become increasingly accessible, with consumers seeking infusions for hydration, recovery, wellness support, and healthy aging. As these services grow in popularity, however, Dr. Aronov believes medical oversight and consumer education are more important than ever.

Instead of asking patients to select an infusion from a predetermined menu, Alpha Vital Elite Precision Medical IV begins with an individualized medical assessment.

Dr. Aronov reviews each patient’s relevant medical history, current medications, allergies, laboratory results, recent illnesses, symptoms, and potential risk factors before determining whether an infusion is medically appropriate.

Most importantly, she says, the evaluation must be completed before any form of supportive IV care is considered.

“The first question is not, ‘Which IV should this patient receive?’” Dr. Aronov said. “The first question is, ‘Should this patient receive an IV at all?’ Only after that determination is made should an appropriate supportive approach be considered.”

Her background in anesthesiology significantly shaped that philosophy. Anesthesiologists routinely administer intravenous medications while continuously evaluating how a patient’s heart, blood pressure, breathing, oxygen levels, and overall physiology respond. That experience has made vigilant monitoring, clinical preparedness, and direct physician involvement fundamental to Dr. Aronov’s approach to wellness care.

“A physician’s name on a document is not an emergency plan,” Dr. Aronov said. “What matters is the training, clinical judgment, and physical presence of the physician who can immediately recognize and manage a complication at the patient’s side.”

Five Questions Consumers Should Ask Before IV Therapy

Dr. Aronov encourages consumers to look beyond luxurious surroundings, marketing claims, or extensive infusion menus—and instead examine the medical infrastructure behind the IV service they are considering.

Before undergoing IV therapy, she believes every patient should ask:

1. Who reviewed my medical history and determined that IV therapy is appropriate for me?
2. Who selected the ingredients, dosages, and infusion rate?
3. Who will monitor my heart rate or rhythm, blood pressure, and oxygen level during the infusion?
4. Who is physically present if I experience an adverse reaction?
5. What can that person do before emergency medical services arrive?

At Alpha Vital Elite Precision Medical IV, Dr. Aronov says monitoring vital signs and maintaining immediate access to oxygen, emergency medications, and emergency-response equipment are integral parts of the practice’s safety model. As a physician trained in Advanced Cardiovascular Life Support, she remains physically present to evaluate patients and respond if a patient’s condition changes unexpectedly.

“Calling 911 is important, but it cannot be the entire emergency plan,” Dr. Aronov said. “The body does not wait for an ambulance. The first few minutes matter.”

Dr. Aronov emphasizes that this philosophy is not intended to diminish the essential roles of nurses, nurse practitioners, physician assistants, or other healthcare professionals. Rather, she wants consumers to understand the specific model of care being offered, the level of monitoring available, and who is physically present, medically trained, and prepared to intervene if an unexpected situation develops.

Moving Beyond One-Size-Fits-All Wellness

Personalization has become one of the wellness industry’s most frequently used terms, but Dr. Aronov defines it differently.

In her practice, individualized IV care does not mean simply adding more ingredients to an infusion. It means determining what belongs, what does not, how individual components interact with one another, and whether the patient should receive the IV at all.

“An IV bag is not a smoothie,” Dr. Aronov said. “Every ingredient has its own chemistry, and not every substance belongs in the same bag.”

IV ingredients may have different requirements involving compatibility, concentration, pH, diluent, storage, light protection, stability, and administration rate. Depending on the substances involved, compatibility and stability must be evaluated before components are combined. Some components may require separate preparation or sequential administration.

“These are medication-safety principles—not optional details,” Dr. Aronov said. “Complex IV combinations require appropriate knowledge of compatibility, stability, sequencing, and administration. Placing every requested ingredient into one IV bag for convenience is not personalization. The integrity of every component has to be considered. If you fail to preserve the integrity of the component, what are you actually delivering—the intended substance or simply the promise of it?”

“Individualized, elite IV care is not defined by adding more vials to the same bag or by providing an infusion wherever the patient feels more comfortable,” she continued. “A comfortable environment cannot replace appropriate medical screening, monitoring, emergency preparedness, and clinical judgment. True individualization is about patient safety: removing what does not belong, separating components when necessary, protecting the integrity of what remains, monitoring the patient’s response, and making the safest decision for that individual—even when that decision is not to proceed.”

Alpha Vital Elite Precision Medical IV offers supportive protocols focused on hydration, recovery, healthy aging, general wellness, joint support, digestive wellness, skin support, brain wellness, and support for individuals with chronic health concerns. Each protocol serves as a framework rather than an automatic formula selected from a menu and is considered only after an individualized medical evaluation.

These services are designed to complement—not replace—the care provided by a patient’s primary physician or specialist.

When Common Symptoms May Warrant Medical Evaluation

Dr. Aronov also cautions against addressing broad symptoms without first considering their potential underlying causes.

Fatigue is one example.

“Fatigue is not a diagnosis,” Dr. Aronov said.

Low energy can have many possible causes, including poor sleep, anemia, thyroid disorders, infection, medication side effects, or other conditions that may require appropriate medical evaluation. Dr. Aronov believes wellness treatments should never mask a symptom that warrants further investigation.

“I do not treat the name printed on an IV menu,” she said. “I evaluate the individual sitting in front of me.”

Alpha Vital Elite Precision Medical IV positions its wellness services as supportive care—not as a replacement for primary or specialty care, prescription medications, or established medical treatment. The practice also avoids suggesting that IV therapy can cure disease or reverse biological aging.

“To me, healthy aging means supporting function, resilience, independence, and quality of life—not selling the promise of immortality,” Dr. Aronov said.

Science Before Marketing

Long before entering medicine, Dr. Aronov developed a deep respect for scientific rigor.

She studied biochemistry at Stony Brook University and worked in laboratory research, including at Regeneron Pharmaceuticals, before pursuing medicine and anesthesiology.

“Cells do not respond to marketing,” Dr. Aronov said. “They respond to chemistry, amount, timing, and their surrounding environment.”

Her research background taught her that a scientifically compelling concept does not automatically translate into a demonstrated benefit for patients. Anesthesiology later reinforced another principle: even an appropriate substance can become problematic when administered to the wrong patient, at the wrong dose, too quickly, or in an incompatible combination.

That concern is particularly relevant to the growing wellness-industry trend of placing numerous ingredients into a single IV bag.

“An IV bag is not a smoothie. Adding more ingredients does not automatically create a better treatment,” Dr. Aronov said.

Dr. Aronov emphasizes that substances considered for an infusion must be evaluated not only individually but also for compatibility, stability, concentration, administration rate, and other formulation considerations when combined.

“If you fail to preserve the integrity of a component, what are you actually delivering—the intended substance or simply the promise of it?” she said.

Before recommending any intervention, Dr. Aronov says she considers three fundamental questions: Does it make scientific sense? What does the evidence actually show? Is it medically appropriate for this particular patient?

From Physician to Patient

Dr. Aronov’s approach became deeply personal after her breast cancer diagnosis and mastectomy.

Experiencing illness from the other side of the medical relationship gave her a new understanding of the uncertainty patients face—and of their need for clear answers, thoughtful options, and realistic hope.

“Breast cancer placed me on the other side of medicine,” Dr. Aronov said. “It taught me that patients need hope, but they also deserve honesty. That is why I will never promise a cure or make claims that science cannot support.”

Today, those three perspectives—the laboratory scientist, the anesthesiologist, and the patient—shape the philosophy behind Alpha Vital Elite Precision Medical IV.

As the boundaries between medicine and wellness continue to evolve, Dr. Aronov believes wellness care should not abandon the principles of medical safety simply because it is delivered in an environment that feels more comfortable, luxurious, or consumer-friendly.

“A patient’s home may feel comfortable and familiar, but comfort should never be confused with clinical preparedness,” Dr. Aronov said. “The surroundings may change, but the patient’s physiology and the potential medical risks do not.”

She also emphasizes that professional credentials should be considered alongside the specific training, experience, emergency preparedness, medications, monitoring capabilities, and equipment available in the setting where an infusion is administered.

For Dr. Aronov, convenience should never take priority over patient safety. Alpha Vital Elite Precision Medical IV is built around the belief that an elevated, patient-centered wellness experience and rigorous medical decision-making can coexist without compromising safety.

“Science taught me to remain curious. Anesthesiology taught me precision. Becoming a patient taught me humility,” Dr. Aronov said. “Those three lessons guide every decision I make.”

About Alpha Vital Elite Precision Medical IV

Alpha Vital Elite Precision Medical IV is a physician-directed medical wellness practice led by Dr. Violeta Aronov, a board-certified anesthesiologist. The practice takes a medically guided approach to IV therapy and wellness services, with an emphasis on patient screening, physician oversight, monitoring, safety, and individualized treatment decisions.

Its services are designed to support areas including hydration, recovery, healthy aging, and overall wellness while complementing—not replacing—appropriate primary and specialty medical care. Dr. Aronov works in coordination with rheumatologists, dermatologists, gastroenterologists, primary care physicians, and other treating healthcare professionals when appropriate to provide supportive adjunctive care.

Media Contact Details
Liana Zavo
Email: Send Email

Authors Andrea Cataneo and Heidi Prudente announce their new book, Wives in Law, sharing the unlikely friendship that transformed their blended family and offering a new perspective on assumptions, kindness and life after divorce.

New York, USA

Andrea Cataneo and Heidi Prudente are announcing the release of their new book, Wives in Law: A Story Of Unexpected Friendship, an intimate and unexpected story about two women who were supposed to be rivals but instead became best friends.

There is just one detail that makes their friendship unusual: Heidi is the first wife of Andrea’s husband, Dan.

Today, when Andrea walks into a family gathering, Heidi is often one of the first people she looks for—and Heidi looks for Andrea, too. They have shared holidays, vacations, weddings, difficult moments, grandchildren and years of laughter.

Wives in Law tells the story of everything that happened in between and challenges the traditional post-divorce narrative that first wives and current wives must exist on opposite sides of a family.

“I very quickly stopped referring to Heidi as Dan’s ex-wife and started calling her his first wife, because ‘ex’ just never sounded very respectful to me,” Andrea says.

Before meeting Heidi, Andrea admits she had formed assumptions based on what she had heard and observed. But when the two finally met face-to-face, nearly a year into Andrea’s relationship with Dan, those assumptions quickly began to disappear.

“My reaction was pretty immediate: she’s cool, she seems genuine, I like her,” Andrea recalls.

More importantly, Andrea and Heidi discovered they already shared something far greater than any potential differences: their daughters came first.

For Heidi, learning to let go of comparison became equally important.

“What changed for me was realizing that nobody needed to win,” Heidi says. “Andrea having an important place in the family didn’t take anything away from mine. There was room for both of us.”

That philosophy gradually changed the entire family dynamic.

Andrea and Dan were deliberately engaged for four years before marrying, giving their daughters time and space rather than forcing an instant blended-family structure.

“Whatever complexities belonged to the adults, the girls didn’t need to carry them,” Andrea says.

Over the years, birthdays, weddings and holidays were celebrated together. Vacations followed, and eventually grandchildren became part of a family that no longer felt divided between “before” and “after.”

“Children, even adult children, shouldn’t have to manage the adults,” Andrea says. “They shouldn’t need an emotional seating chart for every family gathering.”

Heidi agrees that their children and grandchildren have become the greatest beneficiaries of the relationship.

“To them, this isn’t unusual. It’s simply their family,” Heidi says. “They don’t have to split themselves in half to love everyone.”

Two Women, Two Different Backgrounds, One Shared Philosophy

Andrea and Heidi bring different professional and personal experiences to Wives in Law, but both have built careers centered around communication, relationships and understanding people.

Andrea is an accomplished attorney and deal lawyer whose professional career has been built around navigating complex relationships, competing interests and negotiations. Her legal background has taught her the importance of listening to different perspectives, lowering the temperature when disagreements arise and recognizing that two people can see the same situation very differently without either person needing to “win.”

Those lessons became deeply personal as Andrea navigated her relationship with Heidi.

During the writing of Wives in Law, Andrea says there were moments when Heidi would respond to a memory by saying, “That’s not how I remember it.”

Rather than insisting that her own version was correct, Andrea learned to make room for both perspectives.

“I didn’t need my version to win,” Andrea says. “I just needed to make room for hers.”

Heidi is a longtime business owner, children’s author and the creator of Kind Isn’t Weak, a personal platform built around a message that runs through much of her writing and philosophy: kindness, empathy and standing up for others are signs of strength, not weakness.

For Heidi, that belief is also reflected throughout Wives in Law. Choosing kindness does not mean ignoring boundaries, minimizing difficult experiences or pretending conflict never existed. It means recognizing that respect and empathy can sometimes create possibilities that resentment cannot.

Together, Andrea’s experience navigating complex negotiations and Heidi’s commitment to kindness and empathy give Wives in Law a perspective that extends beyond their own family story.

Respect Before Friendship

The authors are clear that their friendship is not intended to become a new expectation for every divorced or blended family.

“We know what Heidi and I have is rare, and neither of us takes that for granted,” Andrea says. “Best friendship may be an extraordinary outcome, but it doesn’t have to be the goal.”

Instead, Wives in Law asks families to consider something more attainable: What could change if the person on the other side stopped being viewed automatically as the enemy?

“Start much smaller than friendship,” Andrea says. “Maybe you just make the next interaction five percent better. A little less assumption, a little more curiosity, one unexpected kindness. Sometimes very big changes begin in surprisingly small ways.”

Andrea and Heidi do not agree on everything. Their friendship developed not because their differences disappeared, but because they learned that disagreement did not have to eliminate respect.

Their relationship was also never the result of one dramatic reconciliation. It grew naturally through conversations, changing perceptions, shared family milestones and the realization that they genuinely enjoyed one another.

“What I love most is how ordinary our unusual family has become,” Andrea says.

For Heidi, the experience ultimately reflects the same message at the heart of her work and Kind Isn’t Weak: kindness can be powerful enough to change the dynamics of an entire family.

“Friendship was the unexpected gift in our story,” Heidi says. “A healthier, kinder family was the much bigger one.”

About Wives in Law: A Story of Unexpected Friendship

With the release of Wives in Law, Andrea Cataneo and Heidi Prudente are inviting readers to reconsider what family can look like after divorce—and what becomes possible when assumptions give way to curiosity, competition gives way to respect, and kindness is recognized as a form of strength.

Two women who might easily have spent their lives avoiding one another now routinely walk into family gatherings looking for each other.

Wives in Law is their story of everything that happened in between.

Media Contact Details
Liana Zavo
Email: Send Email

Boston-based biotechnology company targets commercial-scale production beginning with cocoa as it advances a $25 million Series B2 financing round

BOSTON, MA

GALY, a biotechnology company developing plant-based products through biomanufacturing, is advancing its commercial strategy to create a more stable, scalable and resource-efficient supply chain for some of the world’s most widely consumed products, beginning with cocoa.

Founded in 2019 and headquartered in Boston, GALY is developing technology designed to grow plant-based products directly in controlled production environments rather than relying exclusively on traditional agricultural cultivation. The company’s approach combines plant cell biology, fermentation, process optimization and scalable manufacturing.

The broader objective is ambitious: change how essential agricultural ingredients are produced while addressing challenges surrounding supply-chain volatility, land use, water consumption, carbon impact and product consistency.

According to company materials, GALY’s platform is designed to achieve production that is 10 times faster and 500 times more productive, while targeting 100% supply-chain stability and approximately 80% reductions in land, water and carbon requirements compared with conventional approaches.

Cocoa as the Next Commercial Opportunity

GALY is initially focusing its commercial strategy on cocoa, an ingredient facing increasing attention as global prices, climate pressures and supply-chain challenges affect chocolate manufacturers and food companies.

Rather than depending solely on cocoa grown and harvested from farms, GALY aims to produce customizable cocoa through plant-cell cultivation in brewery-style tanks.

The company says its technology allows it to control four important components affecting cocoa flavor — genetics, elicitation, fermentation and roasting — within an integrated system.

GALY has developed a library of more than 200 seed cell lines spanning more than 14 genotypes, according to its investor materials. This approach is intended to provide manufacturers with greater control over flavor profiles while creating a more predictable and traceable ingredient supply.

The company reports that its cocoa can be produced significantly faster than field-grown cocoa while using fewer natural resources and avoiding certain agricultural contaminants, including pesticide residue and mycotoxins.

GALY has completed its self-GRAS process and filed its FDA GRAS dossier. Its current roadmap calls for its first commercial batch to ship in 2026, followed by initial commercial revenue in 2027.

From Biotechnology to Commercial Scale

One of GALY’s differentiators is its focus on moving biotechnology beyond laboratory development and into industrial-scale manufacturing.

The company plans to utilize retrofitted fermentation infrastructure and co-located manufacturing facilities near breweries and sugar mills, an approach intended to reduce capital requirements while allowing production capacity to expand alongside customer demand.

Its proposed scale-up strategy progresses from a proven 2-kiloliter pilot to 6-kiloliter production, followed by multiple 6-kiloliter units and ultimately 50-kiloliter commercial-scale units.

GALY projects revenue of approximately $4 million in 2027, $19 million in 2028, $49 million in 2029, $125 million in 2030, $238 million in 2031 and $422 million in 2032. These figures represent company projections and are forward-looking rather than guaranteed results.

The company currently projects reaching EBITDA break-even in 2028 and becoming cash-flow positive in 2029.

A Platform Extending Beyond Cocoa

While cocoa represents GALY’s immediate commercial focus, the company is building what it describes as a product-agnostic biocrafting platform capable of addressing additional plant-derived materials.

GALY has already demonstrated its technology in cotton. The company reports that its cultivated cotton reached Technology Readiness Level 4 and demonstrated the ability to tune cellulose characteristics through biomanufacturing.

GALY also identifies coffee, vanilla, citrus, saffron and other plant-derived ingredients as potential opportunities within a substantially larger addressable market.

The company’s long-term thesis is that biomanufacturing could complement conventional agriculture by providing manufacturers with a more controlled source of ingredients while reducing exposure to climate events, geographic constraints and unpredictable commodity markets.

Commercial Strategy Targets Food Service First

GALY plans to initially pursue the food-service sector, including chefs, hotels, bakeries, cafés, coffee chains and restaurants, before expanding further into premium chocolate, consumer packaged goods, private-label products and ingredient and flavor companies.

Company materials cite existing commercial activity involving hospitality and food-service organizations as evidence of early market interest.

Rather than attempting to replace the entire cocoa industry, GALY’s strategy centers on capturing a targeted portion of the premium market where quality, consistency, traceability and supply reliability can command significant value.

Financing the Next Stage

GALY is currently pursuing a $25 million Series B2 financing round, according to its materials, with a targeted first close of $15 million.

The company reports having raised approximately $65 million to date and lists a pre-money valuation of approximately $200 million for the current round.

The additional capital is intended to support GALY’s transition from technological validation toward commercial manufacturing and scale.

The company’s leadership team brings experience spanning biotechnology, consulting, venture capital and industrial commercialization, supported by a scientific advisory board with expertise in bioprocess engineering, plant-cell biomanufacturing, biochemistry and systems biology.

GALY has also received industry recognition for its technology, including recognition from the H&M Global Change Award, LVMH Innovation Award, TIME Best Inventions and Edison Awards.

As global food and consumer-product companies confront increasing pressure to secure reliable and sustainable ingredient supplies, GALY is positioning biomanufacturing as another potential path forward.

Its proposition is straightforward but potentially transformative: some of the products traditionally grown across thousands of acres may increasingly be produced through controlled biological manufacturing — delivering the ingredients consumers already know while fundamentally changing how they reach the market.

About GALY

GALY is a Boston-based biotechnology company founded in 2019 that develops plant-based products through cellular agriculture and biomanufacturing. The company is building a scalable platform designed to produce agricultural ingredients and materials in controlled environments, beginning with cocoa and building upon its previous work in cultivated cotton. GALY’s mission centers on developing more predictable and resource-efficient supply chains for globally important products.

Media Contact Details
Liana Zavo
Email: Send Email